Nantomics, LLC
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 20, 2026 · next Dec 18
- 2 fees due Jan 2 to 9, 2027 · next Jan 2
- 1 fee due Feb 8, 2027The maintenance fee for Iterative Discovery of Neoepitopes and Adaptive Immunotherapy and Methods Therefor (US 11,717,564) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for A Method of Treating a Tumor in a Patient Based on an Immune Gene Expression Signature (US 11,756,651) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 3 fees due May 5 to 21, 2027 · next May 5
- 2 fees due Jul 14 to 16, 2027 · next Jul 14
- 1 fee due Aug 20, 2027The maintenance fee for Systems and methods for genetic analysis of metastases (US 11,908,588) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Digital Histopathology and Microdissection (US 10,607,343) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 4 fees due Oct 2 to 14, 2027 · next Oct 2
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,347,361 | Genome Explorer System to Process and Present Nucleotide Variations in Genome Sequence Data In force · High confidence | In force | High confidence | |
| US 10,323,285 | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 10,620,184 | SRM/MRM Assay for the Cyclin-Dependent Kinase Inhibitor 2A (p16) protein In force · High confidence | In force | High confidence | |
| US 10,736,884 | Compositions and Methods of RIT1 Inhibition In force · Medium confidence | In force | Medium confidence | |
| US 12,404,490 | AGGF1 immunogenic compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 10,339,274 | Viral Neoepitopes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,623,001 | Compositions And Methods For Viral Cancer Neoepitopes In force · High confidence | In force | High confidence | |
| US 12,080,382 | Viral Neoepitopes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,532,089 | Iterative Discovery Of Neoepitopes And Adaptive Immunotherapy And Methods Therefor In force · High confidence | In force | High confidence | |
| US 11,717,564 | Iterative Discovery of Neoepitopes and Adaptive Immunotherapy and Methods Therefor In force · High confidence | In force | High confidence |
Also on record, not counted in the 56: 16 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 8 abandoned · 44 no status recorded